The contract provides coverage of ConfirmMDx testing at the Medicare rate for veterans within the VA health system.
ConfirmMDx is an epigenetic tissue-based test for the early detection of prostate cancer, specifically aimed at addressing false-negative biopsy concerns.
The deal marks the latest in a series of distribution agreements MDxHealth has recently signed for the SelectMDx test.
The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.
The insurer operates Blue Cross and Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma, and Texas, and will now cover ConfirmMDx for its customers.
The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.
Biotechnology company SouthGenetics will distribute the prostate cancer test in countries including Argentina, Chile, Mexico, Peru, Panama, and Venezuela.
The European Health Centre Innovation will now distribute SelectMDx and ConfirmMDx to its urology customers throughout the country.
The positive coverage determination is one of several the company has received in recent months from various insurance companies for the ConfirmMDx test.
With the inclusion of ConfirmMDx in the Medi-Cal program, MDxHealth will seek access for the test in other state Medicaid programs.
The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.
An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.
The US Department of Agriculture presents a new blueprint for animal genomic research.
In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.